Financial Results from 1 Jan 25 to 31 Mar 26

Summary by AI ^BETAClose X

Beximco Pharmaceuticals PLC has released preliminary financial results for the year ended 30 June 2025, reporting a consolidated net profit after tax of Tk. 6,998,869,709, an increase from Tk. 5,866,771,470 in the prior year, with earnings per share rising to Tk. 15.56 from Tk. 13.07. The company also provided unaudited results for subsequent periods, showing strong year-on-year growth in net revenue and profit before and after tax for the nine months ended 31 March 2026, with net revenue up 8.1% to Tk. 13,627.8 million and profit after tax up 30.6% to Tk. 2,254.4 million in the third quarter. These announcements are being made following consent from the Bangladesh Securities and Exchange Commission, and the company expects to resume trading on AIM once full accounts are published, pending ongoing legal proceedings.

Disclaimer*

Beximco Pharmaceuticals PLC

24 June 2026

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation 596/2014 which is part of English Law by virtue of the European (Withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

BEXIMCO PHARMACEUTICALS PLC.

Financial Results for the Periods from 1 January 2025 to 31 March 2026

Beximco Pharmaceuticals PLC. ("Beximco Pharma" or "the Company"; AIM Symbol: BXP, LEI No.:213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients today announces the preliminary results for the full year ended 30 June 2025 and unaudited financial results for the following periods:

· Third quarter and nine months ended 31 March 2026 (unaudited)

· Second quarter and six months ended 31 December 2025 (unaudited)

· First quarter ended 30 September 2025 (unaudited)

· Third quarter and nine months ended 31 March 2025 (unaudited)

These results are being announced following consent from the Bangladesh Securities and Exchange Commission (BSEC), allowing the Company to convene a meeting of its elected Board of Directors for the purpose of considering, approving and publishing the pending financial statements.

Today's publication of preliminary results for the full year ended 30 June 2025 reflects necessary disclosures as required in Bangladesh. The Company expects to publish its full accounts later this week. Once the full accounts have been published, the Company will seek to resume trading on AIM. Further announcements will be made as appropriate in relation to this point.

As previously indicated, the Company has been unable to hold a meeting of the Board of Directors to approve and publish financial results due to matters arising from pending legal proceedings before the High Court Division of the Supreme Court of Bangladesh regarding the Writ Petition No. 525 of 2025 (challenging the proposed appointment by the Bangladesh Securities and Exchange Commission (BSEC) of nine additional independent non-executive directors to the Company's Board) and Writ Petition No. 1243 of 2026 (challenging the BSEC's order to hold a Board Meeting onboarding the nine additional independent directors). The hearing of the writ petitions are currently ongoing and further announcements will be made as appropriate.

Financial Highlights

Annual Comparative Financial Disclosures:

Beximco Pharmaceuticals PLC. and its Subsidiaries (Consolidated)

Particulars	Year ended 30 June 2025	Year ended 30 June 2024
Net Profit after Tax	Tk. 6,998,869,709	Tk. 5,866,771,470
Earnings Per Share (EPS)	Tk. 15.56	Tk. 13.07
Net Asset Value (NAV)	Tk. 53,107,137,101	Tk. 47,949,964,744
Net Asset Value per share (NAVPS)	Tk. 119.04	Tk. 107.48
Net Operating Cash Flow Per Share (NOCFPS)	Tk. 16.19	Tk. 18.75

Beximco Pharmaceuticals PLC. (Stand-alone)

Particulars	Year ended 30 June 2025	Year ended 30 June 2024
Net Profit after Tax	Tk. 6,712,564,301	Tk. 5,610,513,429
Earnings Per Share (EPS)	Tk. 15.05	Tk. 12.58
Net Asset Value (NAV)	Tk. 52,320,598,446	Tk. 47,391,484,377
Net Asset Value per share (NAVPS)	Tk. 117.28	Tk. 106.23
Net Operating Cash Flow Per Share (NOCFPS)	Tk. 15.05	Tk. 17.46

Quarterly Financial Highlights (Consolidated):

	Net revenue		Profit before tax		Profit after tax		EPS
	BDT	YoY change	BDT	YoY change	BDT	YoY change	BDT
Q3 2025-26	13,627.8m	+8.1%	2,906.8m	+29.3%	2,254.4m	+30.6%	-
HY 2025-26	27,800.2m	+15.8%	6,244.7m	+36.0%	4,794.2m	+35.6%	10.58
Q2 2025-26	14,005.3m	+13.9%	3,125.0m	+30.4%	2,392.9m	+29.8%	-
Q1 2025-26	13,794.8m	+17.8%	3,119.7m	+42.2%	2,401.3m	+41.9%	-
Q3 2024-25	12,608.6m	+14.8%	2,247.8m	+31.0%	1,726.0m	+26.3%	-

The full unaudited financial results for each quarter can be found in today's subsequent announcements and on the Company's website: www.beximcopharma.com

Operational highlights (1 January 2025-31 March 2026)

· Launched 14 generics in 22 different presentations in the Bangladesh

o 2 for the first time in Bangladesh

· Completed 63 registrations of 50 products across 21 countries

· Received GMP approval from General Directorate of Medicines, Supplies, and Drugs (DIGEMID), Peru

· Announced plans to launch affordable cystic fibrosis treatments through a collaborative initiative aimed at improving global access to life-saving therapies for patients with unmet medical needs

· Commenced export to Barbados

Beximco Pharma Managing Director, Iqbal Ahmed, commented:

"We're pleased to share our financial results today for numerous periods from 1 January 2025 to 31 March 2026. Over the last 15 months, we have continued to make strong progress both domestically and internationally, providing access to critical medicines for patients across the world. We're proud to have bought fourteen generic products to market domestically, including two products which were not previously available in Bangladesh, in addition to new product registrations in over twenty countries.

These results are testament to the underlying strength of the business. Despite ongoing macro-economic challenges, Beximco Pharma has delivered consistent, profitable growth, and we're confident that our strategy will continue to ensure we deliver affordable and high-quality medicines to patients, whilst also delivering results for shareholders."

For further information please visit www.beximcopharma.com or enquire to:

Beximco Pharma

S M Rabbur Reza, Chief Operating Officer

Tel: +880 2 58611001, Ext. 20111

Mohammad Ali Nawaz, Chief Financial Officer

Tel: +880 2 58611001, Ext. 20030

Mohammad Asad Ullah, FCS

Executive Director & Company Secretary

Tel: +880 2 41060531, Ext. 10140

SPARK Advisory Partners Limited (Nominated Adviser)

Mark Brady / Andrew Emmott

Tel: +44 (0)20 3368 3551 / 3555

SP Angel Corporate Finance LLP (Broker)

Matthew Johnson

Tel: +44 (0) 20 3470 0470

FTI Consulting
Simon Conway / Sam Purewal / Lucy Molloy

Tel: +44 (0)20 3727 1000

Notes to Editors

About Beximco Pharmaceuticals PLC.

Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Since its inception in 1976, the Company remains committed to health and wellbeing of people across all the continents by providing access to contemporary medicines. Company's broad portfolio of generics encompasses diverse delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies.

Beximco Pharma's state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others and it has a geographic footprint in more than 50 countries. More than 6,000 employees are driving the company towards achieving its aspiration to be among the most admired companies in the region.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END